Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 apiece […]
Mergers & Acquisitions
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred […]
Medtronic completes Intersect ENT acquisition
Medtronic (NYSE:MDT) announced that it completed its previously announced $1.1 billion acquisition of Intersect ENT (Nasdaq:XENT). Fridley, Minnesota-based Medtronic announced in August 2021 that it would acquire all outstanding shares of the Menlo Park, Calif.-based sinus implant maker for $28.25 per share in an all-cash transaction. As a result of the transaction, Medtronic acquires Intersect ENT’s Propel and Sinuva drug-eluting […]
Halozyme acquires Antares Pharma for $960M to create drug delivery company
Halozyme Therapeutics (Nasdaq:HALO) announced today that it will acquire Antares Pharma (Nasdaq:ATRS) for approximately $960 million. Both companies’ boards of directors approved the transaction, which will see Halozyme acquire Antares for $5.60 per share in cash. According to a news release, the business combination will create a leading drug delivery and specialty product company with […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]
Fresenius Kabi to acquire Ivenix and its smart infusion system for $240M upfront
Fresenius Kabi announced today that it will acquire Ivenix with plans to bring a comprehensive infusion product portfolio to the U.S. The acquisition, which has a purchase price of $240 million upfront, also includes potential milestone payments linked to achievements of commercial and operating targets. According to a news release, the companies expect the acquisition […]
Glooko acquires Diabnext and its digital health platform for managing diabetes
Glooko announced today that it acquired Diabnext, a developer of a digital health platform for managing diabetes and connecting to healthcare providers. Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed. Palo […]
Second Sight Medical, Nano Precision Medical merging to create therapeutic implant company
Second Sight Medical Products (NSDQ:EYES) and Nano Precision Medical agreed to a merger deal that will focus on drug-device medical implants. The two companies entered into a definitive agreement under which privately held Nano Precision Medical (NPM) will merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM the surviving company […]
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]
Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires
Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on […]
